News

Merck spends $10 billion for Verona, gaining access to its COPD medication
The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.
Physician's Weekly2d
Experts Urge Clinicians to Adopt CAAT Across Airway Diseases
The CAAT governance board recommends transitioning from the COPD Assessment Test to the CAAT and using it for patients with ...
Merck to Buy Verona Pharma in $10 Billion Deal
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
BioPharma Dive3d
Merck to buy Verona and its lung drug in $10B deal
The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...
The American Bazaar1d
Merck to acquire Verona Pharma for $10 billion
This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...
Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B
Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.
Becker's Hospital Review2d
8% rise in hospitalizations follow formulary change of asthma drug: Study
After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...